[HTML][HTML] Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
…, M Nye, L Johnson, J Lord, C Middleton… - The Lancet …, 2021 - thelancet.com
Background No phase 3 trial has yet shown improved survival for patients with pleural or
peritoneal malignant mesothelioma who have progressed following platinum-based …
peritoneal malignant mesothelioma who have progressed following platinum-based …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
…, R FitzGerald, G Saunders, C Middleton… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety and …
[HTML][HTML] Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
…, J Periselneris, E Knox, C Middleton… - Nature …, 2022 - nature.com
Molnupiravir is an antiviral, currently approved by the UK Medicines and Healthcare products
Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces lethal error …
Regulatory Agency (MHRA) for treating at-risk COVID-19 patients, that induces lethal error …
A randomised-controlled phase 2 trial of molnupiravir in unvaccinated and vaccinated individuals with early SARS-CoV-2
SH Khoo, R FitzGerald, G Saunders, C Middleton… - MedRxiv, 2022 - medrxiv.org
Background Molnupiravir was licensed for treating high-risk patients with COVID-19 based
on data from unvaccinated adults. AGILE CST-2 ( NCT04746183 ) Phase II reports safety and …
on data from unvaccinated adults. AGILE CST-2 ( NCT04746183 ) Phase II reports safety and …
Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
…, D Hadjiyiannakis, J Periselneris, E Knox, C Middleton… - 2022 - researchsquare.com
Molnupiravir is an antiviral approved for treating COVID-19, which is thought to drive lethal
error catastrophe. How this drug-induced mechanism of action impacts the emergence of …
error catastrophe. How this drug-induced mechanism of action impacts the emergence of …
A Randomised-Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2 (preprint)
SH Khoo, R FitzGerald, G Saunders, C Middleton… - 2022 - pesquisa.bvsalud.org
Background Molnupiravir was licensed for treating high-risk patients with COVID-19 based
on data from unvaccinated adults. AGILE CST-2 (NCT04746183) Phase II reports safety and …
on data from unvaccinated adults. AGILE CST-2 (NCT04746183) Phase II reports safety and …
Literacy, pedagogy, and prisons: Tracing power in higher education in prison contexts
L Middleton - 2022 - ideals.illinois.edu
Prisons across the world are manifested by—and themselves manifest—racial capitalism,
ableism, and cisheteropatriarchy. At the same time, education, both on the outside and on the …
ableism, and cisheteropatriarchy. At the same time, education, both on the outside and on the …
Analyses to support development of risk-informed separation distances for hydrogen codes and standards.
JL LaChance, WG Houf, L Fluer, B Middleton - 2009 - osti.gov
The development of a set of safety codes and standards for hydrogen facilities is necessary
to ensure they are designed and operated safely. To help ensure that a hydrogen facility …
to ensure they are designed and operated safely. To help ensure that a hydrogen facility …
[PDF][PDF] Data for the Use in Quantitative Risk Analysis of Hydrogen Refueling Stations.
JL LaChance, J Brown, BD Middleton, DG Robinson - 2008 - osti.gov
As part of the US Department of Energy’s Hydrogen, Fuel Cells & Infrastructure Technologies
Program, Sandia National Laboratories is developing the technical basis for assessing the …
Program, Sandia National Laboratories is developing the technical basis for assessing the …
[BOOK][B] … : An Historical Sketch of the City of Salem, and the Towns of Marblehead, Peabody, Beverly, Danvers, Wenham, Manchester, Topsfield, and Middleton
C Webber, WS Nevins - 1877 - books.google.com
… County originally known as Naumkeag, but now divided into the city of Salem, and the towns
of Marblehead, Peabody, Danvers, Beverly, Manchester, Wenham, Topsfield and Middleton…
of Marblehead, Peabody, Danvers, Beverly, Manchester, Wenham, Topsfield and Middleton…
